Our April month in review for hematology breaks down the latest updates to the pipeline, mortality risk in people with sickle cell disease, and our newest multimedia offerings.
An interim analysis of a phase 3 trial displays the effectiveness of prophylaxis with recombinant ADAMTS13, achieving approximately 100% of normal ADAMTS13 levels.
Anemia and iron deficiency are prevalent in heart failure with mildly reduced ejection fraction and may worsen mortality and rehospitalization outcomes.
Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.